Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
1.080
-0.030 (-2.70%)
At close: Nov 5, 2025, 4:00 PM EST
1.070
-0.010 (-0.93%)
After-hours: Nov 5, 2025, 7:27 PM EST
Lexaria Bioscience Revenue
Lexaria Bioscience had revenue of $174.00K in the quarter ending May 31, 2025, with 107.14% growth. This brings the company's revenue in the last twelve months to $615.92K, up 49.85% year-over-year. In the fiscal year ending August 31, 2024, Lexaria Bioscience had annual revenue of $464.28K with 105.24% growth.
Revenue (ttm)
$615.92K
Revenue Growth
+49.85%
P/S Ratio
29.87
Revenue / Employee
$87,989
Employees
7
Market Cap
24.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2024 | 464.28K | 238.07K | 105.24% |
| Aug 31, 2023 | 226.21K | -29.19K | -11.43% |
| Aug 31, 2022 | 255.40K | -467.34K | -64.66% |
| Aug 31, 2021 | 722.74K | 407.95K | 129.59% |
| Aug 31, 2020 | 314.79K | 92.18K | 41.41% |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LEXX News
- 27 days ago - Lexaria Bioscience Corp. Provides Strategic Update - Accesswire
- 5 weeks ago - Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 5 weeks ago - Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - TheNewswire
- 6 weeks ago - Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain - Accesswire
- 2 months ago - Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference - TheNewswire
- 2 months ago - Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone - Accesswire
- 3 months ago - GLP-1 "Arms Race" Broadens to Include Dozens of Companies - Accesswire
- 3 months ago - Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study - TheNewswire